AnaptysBio Inc. Common Stock (ANAB)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach AnaptysBio as a speculative biotech, not a Graham-style bargain. It out-licenses antibody programs tied to Jemperli and Quimilza, so economics depend on partners, milestones, royalties, and trial outcomes. The filings show instability. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $25.6 million and net loss was $52.9 million, or diluted EPS -$1.84. In fiscal Q3 2025, the quarter ended 2025-09-30, revenue was $76.3 million and net income was $15.1 million, diluted EPS $0.52. For fiscal year 2025, the year ended 2025-12-31, revenue was $234.6 million with a net loss of $13.2 million, much better than fiscal year 2024, the year ended 2024-12-31, when revenue was $91.3 million and net loss was $145.2 million, and fiscal year 2023, the year ended 2023-12-31, when revenue was $17.2 million and net loss was $163.6 million. But the fiscal Q1 2026 loss shows that improvement is not yet durable. FairStock's ratios are troubling: Piotroski F-Score 1/9, Altman Z-Score -0.26, ROE -114.55%, P/B 103.61 at the 2026-10-13 close, and trailing free cash flow of only $4.4 million, a 0.3% FCF yield. ROCE of 6.78% and D/E of 21.76 do not offset that. A moat could emerge if Quimilza's Phase 3 data and the GSK collaboration produce durable royalties, but today there is no consistent profit, a negative Altman score, and a $1.3 billion market cap pricing in future success. At $45.59, the price is not supported by current earnings or book value; it is an option on pipeline outcomes. A very large margin of safety would be required.

In plain English: AnaptysBio develops antibody medicines for cancer and inflammatory diseases and works with partners such as GSK to move them forward. The business is not yet steadily profitable: it lost $52.9 million in the quarter ended March 31, 2026, even though it made $15.1 million in the quarter ended September 30, 2025. At $45.59 a share, the company is valued at about $1.3 billion, which looks expensive compared with its current losses and very small cash generation, so much depends on future drug success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer